A liposomal amphotericin B preparation (L-AMP-LRC-1) has been developed and tested successfully in adults by us. This preparation was administered to 23 neonates with candidiasis in an open phase II study. All the 14 assessable patients responded completely to the L-AMP-LRC-1 therapy given at 1 mg/kg for 28 days. Compared to AmBisome, another liposomal formulation of amphotericin B, L-AMP-LRC-1 was effective at lower dose in neonatal candidiasis. Thus L-AMP-LRC-1 appears to be an effective and low cost drug for the treatment of candidiasis.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
neonatal candidiasis
8
liposomal amphotericin
8
phase study
8
treatment neonatal
4
candidiasis
4
candidiasis liposomal
4
amphotericin bl-amp-lrc-1
4
bl-amp-lrc-1 phase
4
study liposomal
4
amphotericin preparation
4
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!